Galmed publishes results from aramchol phase 3 open label part in hepatology

The paper re-iterates the significant anti-fibrotic effect of aramchol 300mg bid in patients with metabolic dysfunction associated steatohepatitis (mash) data is confirmed using 3 objective measurements; nash crn, paired ranked reading, and artificial intelligence (ai) quantitative digital analysis continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (dia) quantify antifibrotic effects with greater sensitivity and larger dynamic range than conventional pathology tel aviv, israel , sept. 25, 2024 /prnewswire/ -- galmed pharmaceuticals ltd.
GLMD Ratings Summary
GLMD Quant Ranking